Absence of Detectable Replication of Human Bocavirus Species 2 in Respiratory Tract by Chieochansin, Thaweesak et al.
Absence of   
Detectable   
Replication of   
Human Bocavirus 
Species 2 in   
Respiratory Tract
Thaweesak Chieochansin, Amit Kapoor,  
Eric Delwart, Yong Poovorawan,  
and Peter Simmonds
Human	bocavirus	(HBoV)	commonly	infects	young	chil-
dren	and	is	associated	with	respiratory	disease;	disease	as-
sociations	of	the	divergent	HBoV-2	species	are	unknown.	
Frequent	 HBoV-2	 detection	 in	 fecal	 samples	 indicated	
widespread	circulation	in	the	United	Kingdom	and	Thailand,	
but	its	lack	of	detection	among	6,524	respiratory	samples	
indicates	likely	differences	from	HBoV-1	in	tropism/patho-
genesis.
S
ince its discovery in 2005 (1), human bocavirus (HBoV) 
has been the subject of intense investigation as a po-
tential cause of human respiratory disease (2). In addition 
to respiratory tract and systemic infections, HBoV DNA 
sequences are frequently detected in fecal samples during 
primary infections (3,4), although a causative role in viral 
gastroenteritis has not been established (5–7). Other parvo-
viruses, including canine and bovine members of the genus 
Bocavirus, can replicate in the gastrointestinal tract and are 
often linked to enteric disease (8,9).
Until  recently,  published  genetic  analyses  reported 
minimal sequence variability of HBoV strains; 2 genetic 
lineages differed in nucleotide sequence by only 2% in the 
virus protein 2 (VP2) gene (10). However, more divergent 
HBoV-like  variants,  provisionally  designated  as  HBoV 
species 2 (HBoV-2), have been identified in fecal samples 
from children in Pakistan and the United Kingdom. These 
viruses show >20% nt sequence divergence (11). Published 
primer sequences for HBoV contain several mismatches 
with HBoV-2 sequences that may prevent their amplifica-
tion (11). Thus, published surveys of HBoV prevalence 
likely report only HBoV-1. Therefore, HBoV-2 may rep-
resent an additional, currently undetected, agent in respira-
tory or enteric disease.
The Study
To investigate HBoV-2, we developed new PCR-based 
detection methods for HBoV by using primer sets highly 
conserved  between  HBoV-1  and  HBoV-2  and  species-
specific primers for HBoV-2. Large-scale screening of per-
sons in the United Kingdom and Thailand was performed 
to compare virus detection frequencies in respiratory and 
fecal samples.
A total of 6,138 respiratory samples from 3,754 per-
sons (2,018 male, 1,722 female, 14 sex unknown) during 
January 1, 2007–June 30, 2008, were obtained from the 
Specialist  Virology  Centre  (Edinburgh,  UK).  Samples 
were not identified but epidemiologic and demographic in-
formation was retained (12,13). Samples comprised 3,065 
nasopharyngeal swabs/aspirates (NPAs) and throat swabs 
(83%). A total of 386 NPAs were obtained from 386 per-
sons (229 male, 154 female, 3 sex unknown) in Bangkok 
during February 16, 2006–July 20, 2008.
A  total  of  2,500  fecal  samples  were  obtained  from 
patients (1,093 male, 1,398 female, and 9 sex unknown) 
in Edinburgh predominantly with gastroenteritis or other 
enteric diseases referred for bacteriologic screening dur-
ing March, June, and September 2008. A total of 530 fecal 
samples were obtained predominantly from children (179 
boys and 138 girls) <5 years of age with diarrhea during 
July 12, 2007–July 25, 2008, and a control group without 
diarrhea  (116  male,  96  female,  1  sex  unknown)  during 
March 4–December 2, 2007, in Bangkok.
DNA was extracted from 200-µL samples of pooled 
or individual specimens (respiratory samples, clarified fe-
cal supernatant) into 40 µL Tris-EDTA buffer as described 
(13). Respiratory and fecal samples from Edinburgh were 
screened in pools of 10; both sample types from Bang-
kok were screened individually. Screening was performed 
by using nested primers conserved between HBoV-1 and 
HBoV-2 in the nucleoprotein (NP)–1 gene (universal prim-
ers: outer sense [position 2589 in DQ000496 st2 isolate (1)]: 
5′-CCWATCGTCYTSYACTGCTTYGA-3′;  outer  anti- 
sense  [2980]:  5′-TAGCYAAGTGTYTWBKGTACACA 
TYAT-3′);  inner  sense  [2727]:  5′-RTKSTGYGGB 
TTCTAYTGGCA-3′;  and  inner  antisense  [2963]:  5′-
TACACATCATCCCARTAAYWACAT-3′).
Amplication conditions were 94°C for 2 min and 35 
cycles at 94°C for 18 s, 50°C for 21 s, and 72°C for 1.5 
min. Amplicons were differentiated by digestion with RsaI. 
Fragments were sized by agarose gel electrophoresis. All 
known HBoV-1 sequences contain an RsaI site between 
nt 2772 and nt 2773, resulting in fragments of 46 bp and 
91 bp; this site is absent in HBoV-2 (undigested amplicon 
length of 237 bp).
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by  using  HBoV2-specific  primers  located  in  the 
nonstructural  (NS)–1  gene  (outer  sense  [1484]:  5′-
AACAGATGGGCAAGCAGAAC-3′;  outer  antisense 
[2031]:  5′-AGGACAAAGGTCTCCAAGAGG-3′;  inner   
sense  [1618]:  5′-AACGATTGCAGACAACGCCTTA 
TA-3′;  and  inner  antisense  [2019]:  5′-TCCAAGA 
GGAAATGAGTTTGG-3′;  sites  matching  all  known 
HBoV-2 variants and not matching HBoV-1 variants are 
underlined.) Amplification conditions were 95°C for 2 min; 
5 cycles at 95°C for 45 s, 53°C for 1 min, and 72°C for min; 
and 35 cycles at 95°C for 30 s, 51°C for 30 s, and 72°C for 
45 s. Positive pools of fecal samples from Edinburgh were 
divided and individual component samples were tested. 
Respiratory and fecal samples from both centers were 
screened by using universal primers, and positive samples 
were digested with RsaI. Undigested amplicons and some 
predicted HBoV-1 fragments (46 bp and 91 bp) were se-
quenced to confirm virus identity. All samples were ad-
ditionally  screened  with  HBoV-2–specific  primers;  16 
undigested samples were positive with HBoV-2–specific 
primers, and all samples identified as HBoV-1 were neg-
ative.  Thus,  species-specific  primers  enabled  effective 
screening of HBoV-2 among samples with high frequen-
cies of HBoV-1.
HBoV-positive fecal samples were generally restricted 
to children <5 years of age (25 from 30 infected children 
whose ages were known) (Figure, panel A; Table). Median 
age of children infected with HBoV-2 (7–12 months) was 
lower than that for those infected with HBoV-1 (1–2 years). 
Infections with HBoV-1 and HBoV-2 were observed at 
low frequencies in older persons (2 and 5 of 1,791 persons 
>35 years of age, respectively). For respiratory samples, 
HBoV-1 infections showed a similar peak incidence among 
children 1–2 years of age (Figure, panel B), similar to that 
observed for fecal samples. This age group was most fre-
quently  infected  in  our  previous  analyses  of  respiratory 
samples from Edinburgh (12). There were no differences 
in frequencies of HBoV-1 or HBoV-2 infection between 
male and female participants. Samples from Bangkok were 
divided into those from persons with diarrhea (327) and 
asymptomatic  controls  (213);  detection  of  HBoV-1  and 
HBoV-2 was restricted to persons with diarrhea (n = 12 
and 2, respectively).
In contrast to its frequent detection in fecal samples, 
HBoV-2 was not detected in >6,500 respiratory samples 
(Table). However, high frequencies of HBoV-1 were re-
corded (14% among children in Bangkok and 3.4% among 
children in Edinburgh); the group from Edinburgh con-
tained  a  substantial  number  of  older  children  (37%  >5 
years of age).
Conclusions
Four conclusions can be drawn from this study. First, 
HBoV-2  circulates  in  3  widely  separated  areas  (United 
Kingdom, Thailand, and Pakistan [11]) and is likely dis-
tributed globally. Second, infections with HBoV-2 show a 
pattern of infecting young children, most <1 year of age. 
Third, absence of HBoV-2 in respiratory samples suggests 
a different tissue tropism that may influence its transmis-
sion route and ability to infect systemically and establish 
persistence. Determining the biologic basis for such differ-
ences will be useful in understanding the pathogenesis of 
HBoV-1–related respiratory disease. Fourth, at a practical 
level, absence of HBoV-2 in respiratory samples indicates 
no likely role for this virus in respiratory disease. Thus, 
screening methods may be adequate for detecting HBoV-
associated respiratory disease. Nevertheless, the unexpect-
edly diverse human bocavirus group may contain addition-
al variants with potential etiologic roles in respiratory or 
other diseases.
Since this study was completed, evidence for an in-
terspecies HBoV-1/-2 recombinant associated with acute 
gastroenteritis has been obtained; the structural gene region 
was most closely related to HBoV-2, and NS1/NP-1 group-
ing with HBoV-1 (14). Although this recombinant would 
have been identified as HBoV-1 by using typing assays 
described in the current study, sequence analysis of HBoV-
1–positive samples in this study and our previous study of 
respiratory samples from Edinburgh and Bangkok (12,15) 
identified only HBoV-1 in the study population, consistent 
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Figure.	Age	distribution	of	study	participants	with	positive	fecal	(A)	
and	respiratory	(B)	sample	results	for	human	bocavirus	(HBoV),	
subdivided	by	HBoV	species.	Circles	indicate	numbers	of	positive	
samples in each category. Analysis of age distribution of persons 
with positive respiratory samples was restricted to samples from 
Bangkok, Thailand.Replication	of	HBoV-2	in	Respiratory	Tract
with all other analyses of this sample type worldwide. Nev-
ertheless, future typing assays should analyze both VP1/2 
and NS/NP-1 to ensure that this and potentially other in-
terspecies recombinants are identified. Investigation of ge-
netic diversity of this group and development of effective 
screening methods for variants of HBoV is required for 
studies of human disease.
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Table.	Frequency	of	human	bocavirus	species	1	and	2	in	
respiratory	and	fecal	samples,	United	Kingdom	and	Thailand*	
Frequency,	no.	(%)	
Sample	type	 Location
No.
tested HBoV-1 HBoV-2
Edinburgh,
UK
2,500 6	(0.2)†	 14	(0.6)†	 Fecal	
Bangkok,
Thailand
530 10	(1.9)	 2	(0.4)	
Edinburgh,
UK
6,138‡ 67	(3.4)‡	 0 Respiratory	
Bangkok,
Thailand
386 55	(14.1)	 0
*HBoV,	human	bocavirus.
†Frequency	among	children	<5	y	of	age:	HBoV-1,	1.4%;	HBoV-2,	3.1%.	
‡Tested	in	241	pools	composed	of	2,294	samples.	Frequencies	were	
determined	by	using	the	Poisson	formula,	f	=	ln(f0).
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